Related Experiment Video
Updated: Oct 9, 2025
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Harnessing dendritic cells for innovative therapeutic cancer vaccines
Joël Plumas1,2,3,4
1Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes.
Purpose Of Review:
The clinical activity of new immunotherapies in cancer, such as anti-Programmed cell death 1 (PD-1)/Programmed death-ligand 1, has revealed the importance of the patient's immune system in controlling tumor development. As in infectious diseases, dendritic cells (DCs) are critical for inducing immune responses in cancer. Unfortunately, autologous DC-based vaccines have not yet demonstrated their clinical benefit. Here, we review recent research using allogeneic DCs as alternatives to autologous DCs to develop innovative therapeutic cancer vaccines.
Recent Findings:
A novel approach using an allogeneic plasmacytoid dendritic cell (PDC) line as an antigen presentation platform showed great potency when used to prime and expand antitumor-specific CD8+ T cells in vitro and in vivo in a humanized mouse model. This PDC platform, named PDC∗vac, was first evaluated in the treatment of melanoma with encouraging results and is currently being evaluated in the treatment of lung cancer in combination with anti-PD-1 immunotherapy.
Summary:
Therapeutic cancer vaccines are of particular interest because they aim to help patients, to mount effective antitumor responses, especially those who insufficiently respond to immune checkpoint inhibitors. The use of an allogeneic plasmacytoid DC-based platform such as PDC∗vac could greatly potentiate the efficacy of these new immunotherapies.
Insights
Allogeneic dendritic cell (DC) vaccines, like PDC*vac, show promise for enhancing cancer immunotherapy. This approach aims to improve patient responses, particularly when combined with immune checkpoint inhibitors like anti-Programmed cell death 1 (PD-1).
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- The patient's immune system plays a crucial role in controlling cancer, as evidenced by the success of immunotherapies like anti-Programmed cell death 1 (PD-1).
- Dendritic cells (DCs) are vital for initiating anti-tumor immune responses, similar to their role in infectious diseases.
- Current autologous DC-based vaccines have not yet achieved significant clinical success in cancer treatment.
Purpose of the Study:
- To review research on allogeneic DCs as a potential alternative to autologous DCs for developing novel therapeutic cancer vaccines.
- To explore the potential of allogeneic DC platforms to enhance the efficacy of existing cancer immunotherapies.
Main Methods:
- Review of recent scientific literature focusing on allogeneic dendritic cell research in cancer therapy.
- Evaluation of a novel allogeneic plasmacytoid dendritic cell (PDC) line, PDC*vac, as an antigen presentation platform.
- Assessment of PDC*vac's ability to prime and expand anti-tumor specific CD8+ T cells in vitro and in vivo.
Main Results:
- The allogeneic PDC platform (PDC*vac) demonstrated significant potency in priming and expanding anti-tumor CD8+ T cells.
- PDC*vac showed encouraging preliminary results in melanoma treatment and is currently under investigation for lung cancer.
- The PDC*vac platform is being evaluated in combination with anti-PD-1 immunotherapy for lung cancer treatment.
Conclusions:
- Allogeneic dendritic cell-based vaccines, such as PDC*vac, represent a promising strategy for therapeutic cancer vaccines.
- This approach could significantly enhance the effectiveness of current immunotherapies, including immune checkpoint inhibitors.
- PDC*vac holds potential for improving anti-tumor responses in patients who do not adequately respond to existing treatments.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy